N-(3-chlorophenyl)-4-nitrobenzo[c][1,2,5]oxadiazol-5-amine | 1422955-24-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: N-(3-chlorophenyl)-4-nitrobenzo[c][1,2,5]oxadiazol-5-amine
• 英文别名: N-(3-chlorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine
• CAS: 1422955-24-5
• 化学式: C₁₂H₇ClN₄O₃
• 分子量: 290.666
• InChiKey: FUUWQJVNALIXDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-氯-4-硝基-2,1,3-苯噁二唑 、 3-氯苯胺 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以75%的产率得到N-(3-chlorophenyl)-4-nitrobenzo[c][1,2,5]oxadiazol-5-amine
  参考文献：
  名称：

  Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor

  摘要：

  Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2 alpha-ARNT heterodimerization by binding an internal cavity of the HIF-2 alpha PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2 alpha-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.

  DOI：

  10.1021/jm301847z

文献信息

• [EN] TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA<br/>[FR] COMPOSÉS DE TÉTRALINE ET DE TÉTRAHYDROQUINOLINE UTILISÉS EN TANT QU'INHIBITEURS DE HIF-2 ALPHA
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2021188769A1

  公开（公告）日：2021-09-23

  Compounds that inhibit HIF-2a, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2a.

  抑制HIF-2a的化合物，以及包含该化合物的方法和合成化合物的方法都在这里描述。还描述了使用这些化合物和组合物治疗多种疾病、障碍和状况，包括至少部分由HIF-2a介导的癌症和免疫相关障碍。
• [EN] INHIBITORS OF HIF-2ALPHA<br/>[FR] INHIBITEURS DE HIF-2 ALPHA
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2021113436A1

  公开（公告）日：2021-06-10

  Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

  本文描述了抑制HIF-2α的化合物，以及含有该化合物的组合物和合成该化合物的方法。还描述了利用这些化合物和组合物治疗各种疾病、紊乱和状况的用途，包括至少部分由HIF-2α介导的癌症和免疫相关紊乱。
• ARYL ETHERS AND USES THEREOF
  申请人：Peloton Therapeutics, Inc.

  公开号：US20170217891A1

  公开（公告）日：2017-08-03

  The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

  本公开涉及HIF-2α抑制剂及其制备和用于治疗癌症的方法。某些化合物在HIF-2α闪烁近距离法、荧光素酶反应法和VEGF ELISA法中表现出很强的效力，并导致在体外携带786-O异种移植瘤的小鼠中肿瘤大小的减小和回归。
• INHIBITION OF HIF-2ALPHA HETERODIMERIZATION WITH HIF1BETA (ARNT)
  申请人：THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20160250216A1

  公开（公告）日：2016-09-01

  Provided is a method of inhibiting heterodimerization of HIF-2α to HIF1β (ARNT) comprising binding certain small molecules to the HIF-2α PAS-B domain cavity but not to HIF1α and inhibiting HIF-2α heterodimerization to HIF1β (ARNT) but not inhibiting HIF1α heterodimerization to HIF1β (ARNT). Those certain small molecules are also referenced synonymously as HIF2-HDI and HIF2α heterodimerization inhibitors and also simply as certain small molecules.

  提供了一种抑制HIF-2α与HIF1β（ARNT）异源二聚化的方法，包括将某些小分子结合到HIF-2α PAS-B结构域的空腔中，但不结合到HIF1α，从而抑制HIF-2α与HIF1β（ARNT）的异源二聚化，但不抑制HIF1α与HIF1β（ARNT）的异源二聚化。这些特定的小分子也被同义地称为HIF2-HDI和HIF2α异源二聚化抑制剂，也被简称为某些小分子。
• TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA
  申请人：ARCUS BIOSCIENCES, INC.

  公开号：US20210317079A1

  公开（公告）日：2021-10-14

  Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.